Rhonda Hellums

Rhonda Hellums joined Silence in April 2021 as VP, Finance and was appointed Chief Financial Officer in February 2022.

Ms. Hellums has over 25 years of corporate finance, accounting, strategic planning, M&A, treasury management, investor, and public relations. Prior to joining Silence in April 2021, she held management positions at several large healthcare companies, including KCI (now 3M+KC) and Genzyme Corporation. She previously served as CFO of Deer Oaks Mental Health and prior to that, CFO of Aratana Therapeutics, a publicly-traded pet therapeutics company.

Ms. Hellums received her BBA degree in Accounting and Information Systems and MBA from the University of Texas at San Antonio.